Somatic mutations in stilbene estrogen-induced Syrian hamster kidney tumors identified by DNA fingerprinting by Singh, Kamaleshwar P & Roy, Deodutta
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Journal of Carcinogenesis
Open Access Research
Somatic mutations in stilbene estrogen-induced Syrian hamster 
kidney tumors identified by DNA fingerprinting
Kamaleshwar P Singh and Deodutta Roy*
Address: Department of Environmental Health Sciences, University of Alabama at Birmingham, Birmingham, AL 35294-0022, USA
Email: Kamaleshwar P Singh - kasingh@uab.edu; Deodutta Roy* - royd@uab.edu
* Corresponding author    
DiethylstilbestrolRandom Amplified Polymorphic DNAMutationsKidney tumors
Abstract
Kidney tumors from stilbene estrogen (diethylstilbestrol)-treated Syrian hamsters were screened
for somatic genetic alterations by Random Amplified Polymorphic DNA-polymerase chain-reaction
(RAPD-PCR) fingerprinting. Fingerprints from tumor tissue were generated by single arbitrary
primers and compared with fingerprints for normal tissue from the same animal, as well as normal
and tumor tissues from different animals. Sixty one of the arbitrary primers amplified 365 loci that
contain approximately 476 kbp of the hamster genome. Among these amplified DNA fragments, 44
loci exhibited either qualitative or quantitative differences between the tumor tissues and normal
kidney tissues. RAPD-PCR loci showing decreased and increased intensities in tumor tissue DNA
relative to control DNA indicate that loci have undergone allelic losses and gains, respectively, in
the stilbene estrogen-induced tumor cell genome. The presence or absence of the amplified DNA
fragments indicate homozygous insertions or deletions in the kidney tumor DNA compared to the
age-matched normal kidney tissue DNA. Seven of 44 mutated loci also were present in the kidney
tissues adjacent to tumors (free of macroscopic tumors). The presence of mutated loci in
uninvolved (non-tumor) surrounding tissue adjacent to tumors from stilbene estrogen-treated
hamsters suggests that these mutations occurred in the early stages of carcinogenesis. The cloning
and sequencing of RAPD amplified loci revealed that one mutated locus had significant sequence
similarity with the hamster Cyp1A1 gene. The results show the ability of RAPD-PCR to detect and
isolate, in a single step, DNA sequences representing genetic alterations in stilbene estrogen-
induced cancer cells, including losses of heterozygosity, and homozygous deletion and insertion
mutations. RAPD-PCR provides an alternative molecular approach for studying cancer
cytogenetics in stilbene estrogen-induced tumors in humans and experimental models. Although
the exact functional importance of mutated loci is unknown, this study indicates that these altered
loci may participate during tumor progression in the kidney.
Introduction
Estrogens are carcinogenic to both humans and experi-
mental animals [1,2]. This is due to their ability to initiate
carcinogenesis and promote the growth and selection that
result in palpable malignancy [2,3]. For example, the
treatment of male Syrian hamsters with natural estrogen
(17 ß estradiol, E2) or synthetic stilbene estrogen (diethyl-
stilbestrol, DES) produces a 90–100% incidence of kidney
Published: 05 March 2004
Journal of Carcinogenesis 2004, 3:4
Received: 01 October 2003
Accepted: 05 March 2004
This article is available from: http://www.carcinogenesis.com/content/3/1/4
© 2004 Singh and Roy; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/4
Page 2 of 10
(page number not for citation purposes)
tumors [3,4]. Ongoing epidemiological studies suggest a
slightly increased threat of breast cancer in women
exposed to DES [1,2]. There is also a growing concern that
DES may be involved in the development of some disor-
ders of the male reproductive system, including an
increased occurrence of testicular cancers [2]. Both E2 and
DES induce cell transformation [5,6]. However, the mech-
anisms by which stilbene estrogen or natural estrogen
cause cell transformation and progression of transformed
cells are not clear.
Treatment of hamsters with DES produces both numerical
(polyploidy, aneuploidy) and structural (deletions, inver-
sions, translocations) changes in the genome of renal cells
[7,8]. Aneuploidy has been detected in SHE cells trans-
formed by both E2 and DES [9,10]. In addition to chromo-
somal aberrations, biochemical changes in the hamster
kidney suggest that DES treatment produces changes at
the genome level [11-13]. Both DES and its metabolites
alter transcriptional activity [14]. Attenuation in DNA
repair coupled with an increase in renal tubular cell pro-
liferation in response to DES exposure may lead to
enhanced genetic instability. DES and/or DES metabolites
may interfere with the spindle apparatus during mitosis
resulting in abnormal segregation of chromosomes [15].
Products of the redox cycling of DES generate free-radical-
driven DNA adducts as well as DES-DNA adducts [16,17].
Chronic treatment of hamsters with DES results in an
increase in the 8-hydroxyguanine in kidney DNA [18].
Despite extensive work on DES, the critical sequence of
molecular events involved in DES-induced carcinogenesis
is not clear.
All human tumors contain genetic alterations. Mutations
in a minimum of six to seven genes are crucial to the proc-
ess of cancer development [19]. Detection of the genomic
regions that are susceptible to stilbene estrogen-induced
mutation is a critical step for the identification of the
genes that may play a role in stilbene estrogen-induced
carcinogenesis. Steroidal estrogen produces genotoxicity
in Syrian hamster embryonic cells, uterine and breast
cells, and induces Hprt mutations in Chinese hamster V79
cells [20-22]. Recent studies show that the reactive DES
metabolite, quinone, increases homologous recombina-
tion in E. coli [23]; both DES and E2 are mutagenic in the
gpt+ Chinese hamster G12 cell line [24]; covalent DNA
adducts formed by both DES quinone and E2 quinone
arrest the progression of DNA synthesis [25]; DNA repair
activity is altered by exposure to DES [26,27]; and kidney
tumors and estrogen-treated kidneys have mutations in
microsatellites [28].
We recently have optimized the Random Amplified Poly-
morphic DNA (RAPD) reaction conditions for both
human and experimental animal DNA [29]. RAPD-PCR
can detect allele losses and gains as well as deletions and
insertions of DNA sequences; thus its resolution is at the
molecular level. Using this method, we have identified
mutations in a novel uncharacterized gene in human spo-
radic breast cancer [30]. In this study, we have used RAPD-
PCR to identify candidate target regions for mutations in
the genome of hamster kidney tumors induced by stilbene
estrogen. We screened 365 loci in DNA from Syrian ham-
ster kidney tumors, observing insertion, deletion, or
intensity differences in 44 loci. We also examined altera-
tions in the genome of uninvolved (non-tumor) sur-
rounding kidney tissue adjacent to tumors with the
objective of screening for molecular lesions that occurred
before the appearance of tumors. Finding common
mutated loci in tumors and uninvolved (non-tumor) sur-
rounding kidney tissue adjacent to tumors indicates that




Sets of twenty OPA, OPC, OPK, OPE, OPAA and OP 26
oligonucleotide random 10-mer primers were purchased
from Operon Technologies (Alameda, CA). AmpliTaq
DNA polymerase (recombinant), Stoffel fragment DNA
polymerase, dNTPs and mineral oil were purchased from
Applied Biosystems (Foster City, CA). The enzyme assay
buffers, 10X PCR buffer II (500 mM KCl, 100 mM Tris-
HCl, pH 8.3) for AmpliTaq and 10X Stoffel buffer (100
mM KCl; 100 mM Tris-HCl, pH 8.3), were received from
Applied Biosystems along with the corresponding
enzymes.
Tumor induction and DNA extraction
Male Syrian hamsters (6–8-weeks old) received a subcuta-
neous implant of a 22-mg DES pellet every three months
[3]. The subcutaneous implant maintains a steady-state
serum estrogen level of 2400 to 2700 pg/ml [4]. After 7
months of treatment, 10 animals were sacrificed, and their
kidneys were excised. Tumors and uninvolved surround-
ing tissues free of visible tumors from the kidneys were
dissected out and frozen in liquid nitrogen. Since the
tumors are small after 7 months of treatment, we pooled
tumors and uninvolved surrounding tissues from the
same treated animals for DNA isolation. We used three
groups of tumor DNA, and each group contained DNAs
from several animals. The control group of six animals
received cholesterol pellets. We separated control tissues
into three groups; each group containing pooled tissues
from two control animals. Nuclear DNA was extracted
from age-matched untreated control, DES-induced tumor
tissues, and uninvolved (non-tumor) surrounding tissue
adjacent to tumors. The concentration of DNA was deter-
mined by spectrophotometry. The quality of DNA wasJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/4
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checked by ethidium-bromide staining after resolution on
a 1% agarose gel.
RAPD-PCR
RAPD-PCR was performed on DNA from untreated con-
trol kidney tissue and DES-induced tumors using a previ-
ously described method [29]. An aliquot of 2 µg DNA was
incubated separately with the restriction enzymes Alu I,
EcoRI, BamHI, HindIII, and HinfI at 37°C. After overnight
incubation for complete digestion of DNA, the restriction
enzyme was heat-denatured by incubation at 70°C for 10
min. The digested DNA samples were then diluted to 20
ng/µl for RAPD analysis. Briefly, the PCR amplifications
were performed in 25 µl of reaction mixture containing
2.5 µl of 10X enzyme assay buffer, 100 µM each of dATP,
dCTP, dGTP and dTTP, 100 nM of random (10-bp)
primer, 1.5 mM MgCl2, 1.5 U of AmpliTaq DNA polymer-
ase and 75 ng of either undigested or restriction enzyme-
digested DNA as template. We used Stoffel fragment
instead of AmpliTaq in Alu digested DNA template. The
amplification was performed in a Perkin-Elmer Cetus
DNA thermal cycler programmed for 45 cycles as follows:
1st cycle of 3.5 min at 92°C, 1 min at 34°C, 2 min at 72°C,
plus 44 cycles of 1 min at 92°C, 1 min at 34°C, 2 min at
72°C, followed by a final extension cycle of 15 min at
72°C. Amplified products were resolved on a 1.5% agar-
ose gel and visualized by ethidium-bromide staining.
Cloning and sequencing of RAPD loci
Amplified fragments were excised from the agarose gel
and DNA was eluted. The eluted DNA was reamplified
with the same random primer, and using the same con-
centrations of reaction mixture constituents and PCR
cycles conditions as described above. The PCR products
were analyzed on an agarose gel to confirm their size and
purity. The reamplified DNA fragments were cloned using
the TA cloning kit (Invitrogen, Carlsbad, CA), following
the protocol provided by the manufacturer. Restriction
analysis of the recombinant plasmid DNA was performed
by the alkaline lysis method to confirm the insert size
[31]. The presence of the correct insert was further con-
firmed by hybridization with the RAPD-eluted DNA frag-
ment. The cloned RAPD-PCR product was sequenced by
the DNA Sequencing Core Facility, Comprehensive Can-
cer Center, UAB. Sequences obtained from our clones
were compared with known sequences in the GeneBank
database using the BLASTn and BLASTx programs.
Data analysis
The size of the genome screened was calculated by adding
the sizes of the all the individual loci amplified by the ran-
dom primers (365 loci amplified by 61 primers). The per-
cent of the genome screened was calculated by dividing
the size of the genome screened by the full length of the
rodent genome × 100. The size of the haploid hamster
genome is estimated to be a similar to that of human, i.e.,
approximately 3 × 109 bp of DNA [32]. Each amplification
product contains two 10-bp priming sites. Thus, we calcu-
lated the size of the genome screened for point mutations
at the primer binding sites as the number of amplification
products × (10 + 10) bp. The size of the genome screened
for length mutation is the value obtained by deducting the
size of the priming sites from total size screened. Loss of
product intensity is associated with copy-number change
as a result of hypoploidy [33]. Similarly gain of product
intensity is associated with copy-number change due to
hyperploidy. The percentage of the genome harboring
point mutation, length mutation, hypoploidy and hyper-
ploidy was calculated by considering the total length
screened (475,630 bp) as the base value.
Results
Seventy random 10-mer primers were used to analyze
instability in the genome of kidney tumors using RAPD-
PCR fingerprinting. These initial screens were conducted
using DNAs that were not digested with restriction endo-
nucleases. Of the 70 primers, 61 produced reproducible
and scorable amplification fingerprints. A total of 365 loci
were amplified by the 61 primers, with an average of 6 loci
per primer. The total length of the genome screened was
approximately 476 kbp (Table 1). Of the 365 loci ana-
lyzed, 44 harbored mutations. The size of the 44 mutated
loci was 50,568 bp, which is 10.63 % of the total length
of the genome screened. The priming sites of the 365
amplified loci contain 7,300 bp (1.53%) of amplified
sequence; the remaining DNA between the priming sites
of the 365 loci contain 468,330 bp (98.47%). Of the 44
mutated loci, 18 were losses, 18 were gains, and the
remaining 8 had intensity differences. In terms of size, the
18 lost loci contain 21,690 bp (4.56%), the 18 gained loci
contain 21,158 bp (4.45%), the 1 hyperploid locus con-
tains 700 bp (0.15%) and the 7 hypoploid loci contain
7,020 bp (1.48%)
Loci without mutation (i.e. similar in control and tumor 
DNA)
Representative photographs of monomorphic (similar
loci) RAPD-PCR fingerprints for DES-induced tumors and
age-matched controls are shown in Fig. 1. Out of the 61
primers, 42 (68.85%) amplified 266 loci that were similar
in control and tumor DNA. The remaining 19 primers
amplified a total of 99 loci, of which 55 were also similar
in DNA from DES-induced tumors and age-matched con-
trols. Although these loci were not informative in reveal-
ing alterations in tumor DNA, loci without mutations
indicate that RAPD-PCR can detect not only mutated
regions but also genomic regions that have not been
affected by tumorigenesis. Thus, the simultaneous ampli-
fication of both the affected/susceptible region and theJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/4
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unaffected region of the genome validates the sensitivity
and reliability of RAPD-PCR fingerprinting.
Loci with mutations common to DES-induced tumors and 
surrounding uninvolved tissue adjacent to tumors
We observed 7 mutated loci amplified by 5 individual
primers (OPA11, 18, 19; OPC14, OPE12) in tumor-free
tissues that were adjacent to tumors, and these same loci
were also altered in the adjacent DES-induced tumors. The
sizes of these seven loci are indicated by bold-face type in
Table 2, and the RAPD fingerprints are shown in Fig. 2.
The mutations consisted of three losses (1.5- and 0.75-
kbp fragments with primer OPA11 and a 0.6-kbp frag-
ment with primer OPA19), and four additions (1.8-, 0.71-
, 2.0- and 1.15-kb fragments with the OPA 18, OPA 19,
OPC 14, and OPE 12 primers, respectively) (Fig. 2). We
performed RAPD-PCR analysis on three pools of DNA
from kidney tissues of age-matched control animals, each
pool containing DNA from two animals. Using the above
sets of primers, we did not observe any change in the
RAPD-PCR fingerprints between the different batches of
untreated controls (data not shown). This indicates that
there were no spontaneous mutations at these loci among
the control animals, or at least that the frequency was too
low to be detected by the analysis. This observation sug-
gests that these mutations were induced as a result of DES
Table 1: Summary of the changes in the genome of stilbene estrogen-induced kidney tumors compared to kidneys of age-match control 
hamsters.
Parameter Examined Control Tumor
Total number of loci screened 365 365
Number of loci with mutations - 44
Length of the genome screened (in bp) ~475,630 ~475,630 (0.016%)
Number of loci showing gains in intensity (hyperploidy) - 1
Number of loci showing reductions in intensity (hypoploidy) - 7
Number of loci gained (insertion) - 18
Number of loci lost (deletion) - 18
Representative RAPD profiles showing similar DNA fingerprint patterns with DNA from stilbene estrogen-induced kidney  tumors (T) and age-matched controls (C) Figure 1
Representative RAPD profiles showing similar DNA fingerprint patterns with DNA from stilbene estrogen-induced kidney 
tumors (T) and age-matched controls (C). Primers used (OPA 04, OPA 10, OPC 15, OPE 11, and OPK 03) are given at the 
bottom of each set of fingerprints.Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/4
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treatment and were not spontaneous mutations associ-
ated with the aging of animals.
Loci with mutations detected only in tumors and not in 
surrounding uninvolved tissue adjacent to tumors
Of the 44 mutated loci that were amplified, 37 (84.10%)
harbored mutations only in tumor DNA and not in the
adjacent uninvolved kidney tissue DNA, as determined
through comparison with kidney DNA from age-matched
control hamsters. Representative fingerprints are shown
in Figs. 2,3,4,5. The sizes of 37 individual loci, and the
sequence of the primers used to amplify them, are given
in Table 2. Of these 37 mutated loci, Fig. 3 shows tumor
DNA-specific losses in the 1.55-, 1.0-, 0.54-kbp products
amplified with primer OPA 08, the 0.3-kbp fragment
amplified with OPK02, the 1.15-kbp fragment amplified
with OPK 09, and the 3.1-kb product amplified by OPK
13. Fig. 4 shows that losses of the 1.95-kbp product ampli-
fied using primer OPC 13, the 1.6- and 0.7-kbp fragments
amplified with primer OPE 03, the 1.6-, and 1.0-kbp
products amplified with primer OPK 16, the 1.75-kbp
fragment produced with primer OP 26-12, and the 1.2-
kbp product amplified with primer OP 26-25 also were
specific to reactions conducted with tumor DNA. In addi-
tion, loss of the 0.3-kbp product amplified with primer
OPC 01 and the 1.1-kb fragment produced with OPC14
was observed in reactions conducted with tumor DNA
and not with DNA from uninvolved (non-tumor) sur-
rounding tissue adjacent to tumors (Table 2). The gain of
18 loci (0.75 kbp with OPA 08, 1.2 kbp with OPA 15, 1.9
and 1.35 kbp with OPK 09 [shown in Fig. 3], and 2.0, 1.5,
1.2 and 0.8 kbp with OPE 03 [shown in Fig. 4]) was
observed in the tumor DNA as compared to control DNA.
Out of the remaining eight loci, seven showed loss of
intensity (the 0.55-kbp fragment amplified with primer
OPA 08 that is shown in Fig. 3; and the 0.7- and 1.5-kbp
products amplified with primer OP 26-07, the 1.6-kbp
fragment amplified with primer OP26-12, and 1.25- and
0.8-kbp fragments produced with primer OP 26-25
shown in Fig. 4), and one showed a gain of intensity (the
0.7-kb produced amplified with primer OPA 17) com-
pared to data from age-matched control kidneys.
Loci with mutations at restriction enzyme recognition sites
Primers that did not reveal differences in fingerprints gen-
erated using undigested control and tumor DNAs were
subjected to RAPD-PCR analyses with DNAs digested with
Alu I, EcoRI, BamHI, HindIII, and HinfI. Only in Alu I-
digested tumor DNA we observed a loss of 0.3-kbp locus
and gain of 0.478- and 0.6-kbp loci with primer OPC01
(Fig. 5). Similarly, a gain of 0.45-kbp and 0.57-kbp frag-
ments was found for Alu I-digested tumor DNA with
primer OPA17 (Fig. 5). Also, Alu I-digested tumor DNA
produced a reduction in the intensity of the 0.65-kbp
Table 2: Summary of the gains, losses and intensity changes in RAPD-amplified products from stilbene estrogen-induced kidney tumors 
compared to age-matched controls. Fragment sizes of the amplification products are given in kilobases (kb). -I represents reduction in 
intensity and +I represents increase in the intensity.
Primer Sequence (5' to 3') Number of Amplification 
Products (no. Variable)
Size (Kb) of variable amplification – products in tumor DNA
Lost Gained Intensity Difference
OPA 08 GTGACGTAGG 7 (5) 1.55 1.0, 0.54 0.75 0.55 -I
OPA 11 CAATCGCCGT 7 (3) 1.5, .75 0.70 -
OPA 15 TTCCGAACCC 5 (1) - 1.2 -
OPA 17 GACCGCTTGT 5 (4) - 0.45, 0.57 0.7+I, 0.62 -I
OPA 18 AGGTGACCGT 4 (1) - 1.8 -
OPA 19 CAAACGTCGG 4 (2) 0.6 .71 -
OPC 01 TTCGAGCCAG 5 (3) 0.3 0.6, 0.478 -
OPC 09 CTCACCGTCC 5 (1) - 2.0 -
OPC 13 AAGCCTCGTC 6 (1) 1.95 - -
OPC 14 TGCGTGCTTG 4 (2) 1.1 2.0 -
OPE 03 CCAGATGCAC 6 (6) 1.6, 0.7 2.0, 1.5, 1.2, 0.8 -
OPE 12 TTATCGCCCC 11 (1) - 1.15 -
OPK 02 GTCTCCGCAA 3 (1) 0.3 - -
OPK 09 CCCTACCGAC 8 (3) 1.15 1.9, 1.35 -
OPK 13 GGTTGTACCC 2 (1) 3.1 - -
OPK 16 GAGCGTCGAA 4 (2) 1.6, 1.0 - -
OP-26-07 TCGATACAGG 5 (2) - - 0.7 -I, 1.5-I
OP-26-12 CTGCTTGATG 5 (2) 1.75 - 1.6-I
OP-26-25 GATCATAGCG 3 (3) 1.2 - 1.25-I, 0.8-IJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/4
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fragment and a gain in intensity of the 0.7-kbp product
amplified with primer OPA17 (Fig. 5). These loci presum-
ably harbored mutations in the Alu I restriction enzyme
recognition sequence.
Characterization of a mutated locus
The 478 bp RAPD amplification product amplified with
primer OPC01 was further cloned and sequenced.
Sequence homology searches revealed that part of the
fragment's sequence (from nucleotide 122 to 252) had
significant similarity (85% identity) with the Syrian ham-
ster gene for Cytochrome P-450 IAI (Fig. 6).
Discussion
This is the first attempt at a comprehensive analysis of
mutations in stilbene estrogen-induced Syrian hamster
kidney tumors. We screened 476 kbp of the hamster
genome in 365 amplified loci. The important finding that
emerged from this study is that the DNA of stilbene estro-
gen-induced tumors showed both qualitative (gains/
losses presumably as a result of point mutations or length
mutations) and quantitative changes (intensity changes
presumably as a result of aneuploidy or polyploidy) in
RAPD-PCR fingerprints. RAPD-PCR fingerprint changes
also were seen in DNA from non-tumor kidney tissue
adjacent to tumors in DES-treated hamsters and these
changes matched changes found in DNA from the tumors.
This suggest that these mutations occurred in early stages
of stilbene estrogen-induced renal carcinogenesis. In addi-
tion, one of the mutated loci had significant sequence
homology with the hamster CypIAI gene.
Exposure of hamsters to DES and E2 results in aneuploidy,
chromosome aberrations, and DNA stand breaks in renal
cells [7,8]. However, these observations provide no
information about specific DNA sequences or gene loci
that have undergone change. Other studies have uncov-
ered very few DNA sequence changes in DES-induced
tumors, including previous attempts at screening for
changes [26,34,28]. RAPD-PCR is a unique method for
identifying specific losses and gains of chromosomal
regions associated with stilbene estrogen tumorigenesis.
The results of this study demonstrate the ability of the
RAPD-PCR to detect and isolate, in a single step, the
Representative RAPD fingerprints showing gains/losses and intensity differences for amplification products indicated by arrow. Figure 2
Representative RAPD fingerprints showing gains/losses and intensity differences for amplification products indicated by arrow 
with size of the amplified fragment (kb) common to DNA from both stilbene estrogen-induced kidney tumors (T) and unin-
volved surrounding tissue adjacent to tumors, i.e., free of macroscopic tumors (M), in comparison with DNA from age-
matched control kidneys (C). Primers used (OPA11, OPA 18, OPA19, OPC 14 and OPE12) are indicated at the bottom of 
each set of fingerprints.Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/4
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genetic alterations in stilbene estrogen-induced cancer
cells, including alterations presumably caused by loss of
heterozygosity, and homozygous deletion or insertion
mutations. RAPD-PCR demonstrated both qualitative and
quantitative changes in DES-induced tumors, which pro-
vides the basis for an alternative molecular approach for
studying cancer cytogenetics that is applicable to stilbene
estrogen-induced tumors from humans as well as experi-
mental models. Thus, RAPD-PCR may be useful for
searching for alterations in archived samples from women
with stilbene estrogen-linked cancers and in those indi-
viduals who are at high risk of developing stilbene estro-
gen exposure-associated cancer.
Although RAPD-PCR provides no direct information on
the functional importance of the mutated loci, analysis of
these genetically-altered loci may provide suggestive evi-
dence for loci that participate in tumorigenesis. Cloning
and sequencing the amplified loci detected in this study
revealed that one of the mutations is in a coding region of
the genome. The sequence of the 478-bp RAPD product
amplified by the OPC01 primer had significant homology
with the Cyp1A1 gene from Syrian hamster. Since Cyp1A1
may be involved in the metabolism of DES to genotoxic
derivatives (see below), amplification of this sequence
could have a functional significance in stilbene estrogen-
induced carcinogenesis. Our present findings indicate that
novel gene(s) susceptible to mutation as a result of stil-
bene estrogen treatment can be identified using this RAPD
screening method. Further characterization of additional
target sites may lead to the identification of additional
genes susceptible to mutation and provide clues as to the
mechanism of DES-induced tumorigenesis.
Previous studies demonstrated that both synthetic and
natural steroidal estrogens are negative in classical bacte-
rial and mammalian gene mutation assays [35,36]. This
led to the conclusion that estrogen is a nongenotoxic and
nonmutagenic chemical [10,37,38], and estrogen was,
therefore, classified as an epigenetic carcinogen [10].
More recently, mutations have been detected in estrogen-
induced kidney tumors: in the catalytic domain of an
important DNA repair enzyme, DNA polymerase ß, and
in microsatellite repeats [26,28]. These mutations could
be due to genomic instability caused by tumor progres-
sion, rather than directly due to estrogen-induced
genotoxicity.
Other studies, however, suggest that estrogens (or estro-
gen metabolites) are genotoxic (see Introduction). DES
and E2 (after conversion to catechol E2) are oxidized to
quinone primarily by cytochrome P450 1A1 [39]. DES or
Representative RAPD fingerprints showing gains/losses and intensity differences of amplification products indicated by arrow. Figure 3
Representative RAPD fingerprints showing gains/losses and intensity differences of amplification products indicated by arrow 
with size of the amplified fragment (kb) for DNA from stilbene estrogen-induced kidney tumors (T), uninvolved surrounding 
tissue adjacent to tumors, i.e., free of macroscopic tumors (M), and age-matched controls (C). Primers used (OPA 08, OPA 15, 
OPK 02, OPK 09, and OPK 13) are indicated at the bottom of each set of fingerprints.Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/4
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estradiol semiquinone also is formed as an intermediate
in the process of oxidation of stilbene estrogen or catechol
estrogens. The semiquinones react with molecular oxygen
and generate superoxide, which is further reduced to the
hydroxyl radical. Various types of DNA damage are pro-
duced by either estrogen metabolites or free radicals bind-
ing covalently to DNA [11-13,16,17]. Recent studies
demonstrate the genotoxicity of DES quinone [23,25] and
both DES and E2 are mutagenic in the gpt+ Chinese ham-
ster G12 cell line [24]. In vivo formation of stilbene estro-
gen quinone, covalent binding of DES to nuclear DNA
[14], and the chromosomal abnormalities observed in the
kidneys of DES-treated Syrian hamsters [7,8] are consist-
ent with a mechanism of DES-induced DNA damage.
Thus, the ability of DES reactive metabolites or free radi-
cals formed during the redox cycling of DES to covalently
modify bases of DNA, arrest the gene replication and pro-
duce mutations suggests that these reactive intermediates
could initiate and promote the formation of DES-induced
kidneys tumors.
Mutation is a largely random phenomenon, and its targets
can be relatively nonspecific. Any mutational analysis
designed to screen mutation in a particular gene or
genomic region may not detect mutations produced by an
otherwise mutagenic carcinogen. This may explain why
Representative RAPD fingerprints showing gains/losses and intensity differences of amplification products indicated by arrow  with size of amplified fragment (kb) for DNA from stilbene estrogen-induced kidney tumors (T) and age-matched controls (C) Figure 4
Representative RAPD fingerprints showing gains/losses and intensity differences of amplification products indicated by arrow 
with size of amplified fragment (kb) for DNA from stilbene estrogen-induced kidney tumors (T) and age-matched controls (C). 
Primers used (OPC 13, OPE 03, OPK 16, OP 26-07, OP 26-12, and OP 26-25) are indicated at the bottom of each set of 
fingerprints.
Representative RAPD fingerprints for Alu I-digested and  undigested DNA from stilbene estrogen-induced kidney  tumors (T) and age-matched control (C) tissue Figure 5
Representative RAPD fingerprints for Alu I-digested and 
undigested DNA from stilbene estrogen-induced kidney 
tumors (T) and age-matched control (C) tissue. Arrows indi-
cate the RAPD loci harboring mutations in the Alu I restric-
tion enzyme recognition sequence. Note that these 
mutations were not detected in the RAPDs from undigested 
DNA using the same primers.Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/4
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many previous studies have failed to detect estrogen-
induced mutation. Thus, the screening of mutations at a
genome-wide level with RAPD-PCR, which is not biased
to any particular gene/genomic region, may be a better
approach for drawing conclusions about the mutagenic
potential of a chemical. RAPD-PCR by itself does not dis-
tinguish between initiating lesions induced by genotoxic
carcinogens and mutations generated during tumor pro-
gression as a consequence of genomic instability. How-
ever, the identification of mutations common to both
stilbene estrogen-induced tumors and the uninvolved
(non-tumor) surrounding kidney tissues adjacent to
tumors strongly suggests that stilbene estrogen treatment
may be responsible for some of the early mutations in the
genome of Syrian hamster kidney.
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